CLINICAL_TRIALS
trial_result
· 2009-06-30
Clinical Trial Update: Recombinant Human Erythropoietin Use in Intensive Care Unit (ICU) Patients: Does it Prevent Acute Renal Failure [Phase 2]
Summary
Phase 2 trial evaluating whether recombinant human erythropoietin given to ICU patients can prevent acute kidney injury; the trial has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University Hospital, Geneva | Conditions: Acute Renal Failure | Phase 2 | Status: COMPLETED